A new study has been conducted by an international team led by researchers at the US National Cancer Institute (NCI), part of the National Institutes of Health (NIH). The findings were published…
Study: Stem-Like T Cells May Help Immunotherapy in Lung Cancer Treatment
In a new study conducted by the Yale Cancer Center, the researchers have found that stem-like T cells in certain lymph nodes may be natural cancer fighters. The findings have been reported…
Study Suggests Biomarker May Help in Predicting Benefits of Immunotherapy
Immunotherapy is a widely used method for treatment of several types of cancers including lung cancer, bladder cancer and more. Immune-based treatments for cancers have raised hope of doctors as well as…
Novel AI Blood Testing Capable of Identifying Lung Cancer with 90% Accuracy
Lung cancer claims over 2 million lives worldwide each year and is the most common cause of cancer death. A new artificial intelligence blood testing technology has been developed by researchers at…
Chemotherapy and Immunotherapy Combination to Provide Effective Lung Cancer Treatment
According to a study published in Science Translational Medicine, a combination of two cancer treatments could provide effective treatment for lung cancer by targeting immune cells involved with formulation of tumors. The…
Combination of Experimental Drugs Shown to Extend Lung Cancer Survival in Mice
According to a new study led by researchers at NYU Grossman School of Medicine and its Laura and Isaac Perlmutter Cancer Center, a combination of experimental drugs has shown to extend survival…
World Lung Cancer Day 2021: Promoting Lung Cancer Awareness
Lung Cancer is the second most common form of cancers in the world. It is the leading cause of cancer deaths among both men and women. It takes more lives yearly than…
LaGrippe Research: Small Cell Lung Cancer (SCLC) Project (2021)
My name is Maggie and I am with LaGrippe Research. We are currently inviting those diagnosed with Small Cell Lung Cancer (SCLC) to participate in our upcoming one-on-one discussion with our moderator….